Achieve Life Sciences is a clinical-stage pharmaceutical company developing cytisinicline as a treatment for nicotine dependence and smoking cessation. The company's lead product candidate, cytisinicline, is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors. Achieve received a Complete Response Letter from the FDA for its NDA in 2026.
Company Info
Upcoming Milestones & Key Dates
Resubmission of cytisinicline NDA after CRL
Clinical Development Pipeline
Recent News
Achieve Life Sciences gets FDA CRL for cytisinicline; UPS puts $48M into cold-chain logistics; AdvanCell is establishing a US headquarters and Jubilant recievs FDA warning letter.
Leadership Team
Chief Executive Officer
Chief Scientific Officer
Careers & Job Openings